Assessment of Auto-antibodies (RF, Anti-CCP, and Anti-RA33) in Rheumatoid Arthritis Patients: Comparative study

Mustafa Dhurgham Hashiam; Hawraa A Ali Aldahhan

doi:10.53730/ijhs.v6nS5.9829

Authors

Mustafa Dhurgham Hashiam Laboratory Investigations Department, Faculty of Science, University of Kufa, Najaf, Iraq
Hawraa A Ali Aldahhan Laboratory Investigations Department, Faculty of Science, University of Kufa, Najaf, Iraq

Keywords:

Rheumatoid arthritis, RF, anti-CCP, anti-RA33, Sensitivity, Specificity

Abstract

Rheumatoid arthritis is a chronic systemic autoimmune disease which is typically present in adulthood, more common in women than men and affecting e0.5- 1% of the adulth population.Many auto-antibodies could be implicated in the pathogenesis of the disease of these Anti-RA33 antibodies and anti-CCP antibodies in addition to rheumatic factor (RF). This case control study was doing during the period from January 2021 to August 2021.Its conducted on (105) patients with RA match with (45) healthy control. RF, anti- CCP and RA33 were positive in 84( 80% ), 89(84.7 %),and 100 ( 96.1 %) patients with RA, respectively. the anti-CCP antibody showed 100% sensitivity for the detection of RA, and the anti-RA33 antibody showed a sensitivity of 96.1%. Anti-CCP demonstrated more favorable predictive values for RA than anti-RA33 and RF. there is a highly significant difference (P≤0.05) when compared between RA patient groups and control group. In this study the mean levels of all auto-antibodies ( RF, anti-CCP, RA33 )were increased significantly(P<0.05) in RA patients(113±81 , 92.3 ±87.5, 336±110),respectively compared with control group .The age group (61-≥70)group appeared significant higher mean level of RF, anti-CCP, RA33 than other age groups.

Downloads

Download data is not yet available.

References

Al-Derzi, A.R., 2017. The Contribution of Serum Anti–cyclic Citrullinated Peptide Antibody and Matrix Metalloproteinase-3 in Predicting the Activity of Rheumatoid Arthritis Disease. Journal of the Faculty of Medicine Baghdad, 59(2), pp.138-144.

Alm, L.M., Fountain, D.L., Cadwell, K.K., Madrigal, A.M., Gallo, G. and Poorafshar, M., 2018. The performance of anti-cyclic citrullinated peptide assays in diagnosing rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol, 36, pp.144-52.

Al-Mughales, J.A., 2015. Immunodiagnostic significance of anti-RA33 autoantibodies in Saudi patients with rheumatoid arthritis. Journal of immunology research, 2015.

Awwad, H.M. and Aboukhamis, I., 2010. Diagnostic performances of anti-cyclic citrullinated peptide antibodies type IgM, IgA and IgG in Syrian patients with rheumatoid arthritis. Clinical Laboratory, 56(3-4), pp.95-102.

Chiad, I.A., Yossef, H.S., Al-Saidi, M.A. and Abbas, M.A., 2015. Evaluation of Some Immunological Markers in the Rheumatoid Arthritis Patients. Iraqi Journal of Science, 56(3C), pp.2488-2493.

Guo, Q., Zheng, K., Fan, D., Zhao, Y., Li, L., Bian, Y., Qiu, X., Liu, X., Zhang, G., Ma, C. and He, X., 2017. Wu-Tou decoction in rheumatoid arthritis: integrating network pharmacology and in vivo pharmacological evaluation. Frontiers in Pharmacology, 8, p.230.

Kaya, S., Kaptanoglu, E., Elden, H. and Hizmetli, S., 2010. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Internal Medicine, 49(6), pp.619-622.

Lashkari, M., Noori, A., Hajiimanouchehri, F., Oveisi, S. and Kazemifar, A.M., 2014. Determination of specificity and sensitivity of anti-RA 33 in diagnosis of early rheumatoid arthritis. Global Journal of Health Science, 6(4), p.292.

Maslyanskiy, A., Lazareva, N., Olinek, P., Schierack, P., Hentschel, C., Cuccato, J., Bogdanos, D.P., Lapin, S.V. and Roggenbuck, D., 2014. Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in Russian patients with rheumatoid arthritis and systemic sclerosis. Journal of immunology research, 2014.

Permana, A. T., Suroto, N. S., Parenrengi, M. A., Bajamal, A. H., Lestari, P., & Fauzi, A. A. (2022). Current update on stroke ischemic management: Stem cell as emerging therapy. International Journal of Health & Medical Sciences, 5(1), 122-128. https://doi.org/10.21744/ijhms.v5n1.1851

Plenge, R.M., Padyukov, L., Remmers, E.F., Purcell, S., Lee, A.T., Karlson, E.W., Wolfe, F., Kastner, D.L., Alfredsson, L., Altshuler, D. and Gregersen, P.K., 2005. Replication of putative candidate-gene associations with rheumatoid arthritis in> 4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. The American Journal of Human Genetics, 77(6), pp.1044-1060.

Zhou, X., Abdullah, N.S., Gobezie, R., Lee, D.M. and Walls, A.F., 2010. Activation of mast cells and their subsets in the synovium in osteoarthritis (OA) and rheumatoid arthritis (RA). Journal of Allergy and Clinical Immunology, 125(2), p.AB178.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937

Sokka, T., Kautiainen, H., Pincus, T., Toloza, S., Pinheiro, G.D.R.C., Lazovskis, J., Hetland, M.L., Peets, T., Immonen, K., Maillefert, J.F. and Drosos, A.A., 2009. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database. Annals of the rheumatic diseases, 68(11), pp.1666-1672.

Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham III, C.O., Birnbaum, N.S., Burmester, G.R., Bykerk, V.P., Cohen, M.D. and Combe, B., 2010. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & rheumatism, 62(9), pp.2569-2581.